Multi-omics Analysis of the Biological Mechanism of the Pathogenesis of Non-alcoholic Fatty Liver Disease

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2024 Aug 12

PMID 39132138

Authors

Jie Lin

Ruyi Zhang

Huaie Liu

Yunzhen Zhu

Ningling Dong

Qiu Qu

Hongyan Bi

Lihua Zhang

Ou Luo

Lei Sun

Mengjuan Ma

Jing You

Affiliations

Soon will be listed here.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a type of liver metabolic syndrome. Employing multi-omics analyses encompassing the microbiome, metabolome and transcriptome is crucial for comprehensively elucidating the biological processes underlying NAFLD.

Methods: Hepatic tissue, blood and fecal samples were obtained from 9 NAFLD model mice and 8 normal control mice. Total fecal microbiota DNA was extracted, and 16S rRNA was amplified, to analyze alterations in the gut microbiota (GM) induced by NAFLD. Subsequently, diagnostic strains for NAFLD were screened, and their functional aspects were examined. Differential metabolites and differentially expressed genes were also screened, followed by enrichment analysis. Correlations between the differential microbiota and metabolites, as well as between the DEGs and differential metabolites were studied. A collinear network involving key genes-, microbiota-and metabolites was constructed.

Results: and , both belonging to Firmicutes; , and from Bacteroidota; and , and from Actinobacteriota were identified as characteristic strains associated with NAFLD. Additionally, differentially expressed metabolites were predominantly enriched in tryptophan, linoleic acid and methylhistidine metabolism pathways. The functions of 2,510 differentially expressed genes were found to be associated with disease occurrence. Furthermore, a network comprising 8 key strains, 14 key genes and 83 key metabolites was constructed.

Conclusion: Through this study, we conducted a comprehensive analysis of NAFLD alterations, exploring the gut microbiota, genes and metabolites of the results offer insights into the speculated biological mechanisms underlying NAFLD.

References

Isabel Alvarez-Mercado A, Navarro-Oliveros M, Robles-Sanchez C, Plaza-Diaz J, Saez-Lara M, Munoz-Quezada S . Microbial Population Changes and Their Relationship with Human Health and Disease. Microorganisms. 2019; 7(3). PMC: 6463060. DOI: 10.3390/microorganisms7030068. View

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

Canbay A, Sowa J . L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs. 2019; 79(Suppl 1):39-44. PMC: 6416231. DOI: 10.1007/s40265-018-1020-5. View

Li C, Pi G, Li F . The Role of Intestinal Flora in the Regulation of Bone Homeostasis. Front Cell Infect Microbiol. 2021; 11:579323. PMC: 7994858. DOI: 10.3389/fcimb.2021.579323. View

Yuan F, Wang H, Tian Y, Li Q, He L, Li N . Fish oil alleviated high-fat diet-induced non-alcoholic fatty liver disease via regulating hepatic lipids metabolism and metaflammation: a transcriptomic study. Lipids Health Dis. 2016; 15:20. PMC: 4736290. DOI: 10.1186/s12944-016-0190-y. View

Musso G, Gambino R, Cassader M, Pagano G . A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010; 52(1):79-104. DOI: 10.1002/hep.23623. View

Douglas G, Maffei V, Zaneveld J, Yurgel S, Brown J, Taylor C . PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020; 38(6):685-688. PMC: 7365738. DOI: 10.1038/s41587-020-0548-6. View

de la Cuesta-Zuluaga J, Corrales-Agudelo V, Velasquez-Mejia E, Carmona J, Abad J, Escobar J . Gut microbiota is associated with obesity and cardiometabolic disease in a population in the midst of Westernization. Sci Rep. 2018; 8(1):11356. PMC: 6063892. DOI: 10.1038/s41598-018-29687-x. View

Zhou W, Zheng Y, Shang J, Wang H, Wang Y, Lu H . Intestinal microecology in mice bearing diethylnitrosamine-induced primary hepatocellular carcinoma. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023; 51(4):438-453. PMC: 10265007. DOI: 10.3724/zdxbyxb-2022-0283. View

10.

Wu H, Tremaroli V, Schmidt C, Lundqvist A, Olsson L, Kramer M . The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional Study. Cell Metab. 2020; 32(3):379-390.e3. DOI: 10.1016/j.cmet.2020.06.011. View

11.

Teunis C, Nieuwdorp M, Hanssen N . Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases. Metabolites. 2022; 12(6). PMC: 9227929. DOI: 10.3390/metabo12060514. View

12.

Jiang X, Yang Q, Qu H, Chen Y, Zhu S . Endogenous -3 PUFAs Improve Non-Alcoholic Fatty Liver Disease through FFAR4-Mediated Gut-Liver Crosstalk. Nutrients. 2023; 15(3). PMC: 9919706. DOI: 10.3390/nu15030586. View

13.

Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett W . Metagenomic biomarker discovery and explanation. Genome Biol. 2011; 12(6):R60. PMC: 3218848. DOI: 10.1186/gb-2011-12-6-r60. View

14.

Marshall J . The gut as a potential trigger of exercise-induced inflammatory responses. Can J Physiol Pharmacol. 1998; 76(5):479-84. DOI: 10.1139/cjpp-76-5-479. View

15.

Xiang H, Gan J, Zeng D, Li J, Yu H, Zhao H . Specific Microbial Taxa and Functional Capacity Contribute to Chicken Abdominal Fat Deposition. Front Microbiol. 2021; 12:643025. PMC: 8010200. DOI: 10.3389/fmicb.2021.643025. View

16.

Fang C, Zhou Q, Liu Q, Jia W, Xu Y . Crosstalk between gut microbiota and host lipid metabolism in a mouse model of alcoholic liver injury by chronic baijiu or ethanol feeding. Food Funct. 2021; 13(2):596-608. DOI: 10.1039/d1fo02892h. View

17.

Powell E, Wong V, Rinella M . Non-alcoholic fatty liver disease. Lancet. 2021; 397(10290):2212-2224. DOI: 10.1016/S0140-6736(20)32511-3. View

18.

Jian J, Nie M, Xiang B, Qian H, Yin C, Zhang X . Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids. Front Pharmacol. 2022; 13:841132. PMC: 9017645. DOI: 10.3389/fphar.2022.841132. View

19.

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.e5. PMC: 5502730. DOI: 10.1016/j.cmet.2017.04.001. View

20.

Ren Z, Fan Y, Li A, Shen Q, Wu J, Ren L . Alterations of the Human Gut Microbiome in Chronic Kidney Disease. Adv Sci (Weinh). 2020; 7(20):2001936. PMC: 7578882. DOI: 10.1002/advs.202001936. View